双鹭药业：XXXX年第一季度报告全文

1、北京双鹭药业股份有限公司2011年第一季度季度报告全文4股票600704中大股份800,400.0060,0001,018,200.008.40%50,400.00期末持有的其他证券投资4,479,760.00-3,502,445.0028.89%49,876.82报告期已出售证券投资损益-0.00合计14,087,060.00-12,120,665.00100%565,716.82§ 4附录4.1资产负债表项目期末余额年初余额合并母公司合并母公司流动资产：货币资金462,617,097.08293,256,648.36445,892,088.25294,144,778.78结算备付

2、金拆出资金交易性金融资产12,120,665.0010,953,760.0011,565,600.0010,418,080.00应收票据1,820,327.881,820,327.881,115,743.411,115,743.41应收账款154,372,188.19153,071,114.16138,822,721.00137,668,732.97预付款项99,044,306.4676,161,575.2258,674,907.7338,371,426.92应收保费应收分保账款应收分保合同准备金应收利息3,392,197.69992,491.923,055,507.91363,335.48应

3、收股利其他应收款1,131,850.9537,476.861,090,182.2530,036,838.56买入返售金融资产存货40,465,337.8642,377,191.6929,522,919.8928,395,154.17一年内到期的非流动资产25,547,000.00245,000.0025,547,000.00245,000.00其他流动资产50,000,000.0050,000,000.00流动资产合计850,510,971.11578,915,586.09765,286,670.44540,759,090.29非流动资产：发放委托贷款及垫款可供出售金融资产80,868,000

4、.0080,868,000.0092,943,000.0092,943,000.00持有至到期投资长期应收款长期股权投资138,148,225.66243,959,206.20133,656,685.27208,967,665.81投资性房地产固定资产179,588,666.20134,018,877.57180,770,347.14135,032,716.19在建工程1,836,310.881,311,925.181,443,232.481,077,446.18工程物资固定资产清理生产性生物资产编制单位：北京双鹭药业股份有限公司2011年03月31日单位：元油气资产无形资产36,329,53

5、3.2216,365,047.5937,275,135.6216,993,798.09开发支出31,104,158.4031,104,158.4030,543,649.4030,543,649.40商誉长期待摊费用2,756,868.512,930,966.49递延所得税资产5,314,712.493,686,880.223,723,183.861,829,329.71其他非流动资产非流动资产合计475,946,475.36511,314,095.16483,286,200.26487,387,605.38资产总计1,326,457,446.471,090,229,681.251,248,57

6、2,870.701,028,146,695.67流动负债：短期借款向中央银行借款吸收存款及同业存放拆入资金交易性金融负债应付票据应付账款10,436,786.0210,279,746.148,051,219.217,865,504.01预收款项4,058,816.074,045,816.072,383,127.872,370,127.87卖出回购金融资产款应付手续费及佣金应付职工薪酬1,997,507.931,769,345.912,044,607.261,781,428.62应交税费29,128,748.8423,003,122.3420,759,152.2815,370,002.47应付利

7、息应付股利其他应付款3,706,041.223,329,001.223,983,897.543,606,857.54应付分保账款保险合同准备金代理买卖证券款代理承销证券款一年内到期的非流动负债其他流动负债976,900.00976,900.00流动负债合计50,304,800.0843,403,931.6837,222,004.1630,993,920.51非流动负债：长期借款应付债券长期应付款专项应付款预计负债递延所得税负债其他非流动负债非流动负债合计负债合计50,304,800.0843,403,931.6837,222,004.1630,993,920.51所有者权益（或股东权益）：实收

8、资本（或股本）252,980,000.00252,980,000.00252,980,000.00252,980,000.00资本公积28,638,856.3827,936,030.1638,902,606.3838,199,780.16减：库存股专项储备盈余公积94,896,632.2394,896,632.2394,896,632.2394,896,632.23一般风险准备未分配利润879,130,433.72671,013,087.18803,972,277.31611,076,362.77外币报表折算差额归属于母公司所有者权益合计1,255,645,922.331,046,825,74

9、9.571,190,751,515.92997,152,775.16少数股东权益20,506,724.06 '20,599,350.62所有者权益合计1,276,152,646.391,046,825,749.571,211,350,866.54997,152,775.16负债和所有者权益总计1,326,457,446.471,090,229,681.251,248,572,870.701,028,146,695.674.2利润表项目本期金额上期金额合并母公司合并母公司一、营业总收入127,031,084.54113,990,297.5489,700,312.9284,235,499.

10、90其中：营业收入127,031,084.54113,990,297.5489,700,312.9284,235,499.90利息收入已赚保费手续费及佣金收入二、营业总成本45,912,709.3749,456,245.2326,342,599.7534,032,237.63其中：营业成本29,210,312.5537,653,102.4712,137,591.8721,892,909.40利息支出手续费及佣金支出退保金赔付支出净额提取保险合同准备金净 额保单红利支出分保费用营业税金及附加1,356,714.121,087,589.541,123,092.05917,415.90销售费用2,3

11、81,287.772,377,287.772,522,081.512,522,081.51管理费用13,601,927.718,796,786.2311,254,020.739,377,430.26财务费用-1,460,882.85-1,302,870.85-947,741.70-931,154.73资产减值损失823,350.07844,350.07253,555.29253,555.29力口：公允价值变动收益（损 失 以“-”号填列）555,065.00535,680.00-1,254,170.45-1,292,562.41投资收益（损失以“-”号 填列）5,165,942.214,501

12、,992.212,082,580.221,091,555.68其中：对联营企业和合 营企业的投资收益编制单位：北京双鹭药业股份有限公司单位：元2011 年 1-3 月汇兑收益（损失以“-”号填 列）三、营业利润（亏损以“-”号填 列）86,839,382.3869,571,724.5264,186,122.9450,002,255.54力口：营业外收入672,183.24172,183.24减：营业外支出10,665.71其中：非流动资产处置损失四、利润总额（亏损总额以“-” 号填列）86,828,716.6769,571,724.5264,858,306.1850,174,438.78减：所

13、得税费用11,763,186.829,635,000.118,973,829.377,143,947.25五、净利润（净亏损以“-”号填 列）75,065,529.8559,936,724.4155,884,476.8143,030,491.53归属于母公司所有者的净 利润75,158,156.4159,936,724.4156,162,311.8543,030,491.53少数股东损益-92,626.56-277,835.04六、每股收益：（一）基本每股收益0.2970.223（二）稀释每股收益0.2960.221七、其他综合收益-10,263,750.00-10,263,750.000.0

14、00.00八、综合收益总额64,801,779.8549,672,974.4155,884,476.8143,030,491.53归属于母公司所有者的综 合收益总额64,894,406.4149,672,974.4156,162,311.8543,030,491.53归属于少 数股东的综合收 益总额-92,626.56-277,835.04本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0.00元。4.3 现金流量表编制单位：北京双鹭药业股份有限公司2011年1-3月单位：元项目本期金额上期金额合并母公司合并母公司一、经营活动产生 的现金流量：销售商品、提供劳务收到的 现金137

15、,873,726.18125,921,689.18100,927,819.1393,438,929.13客户存款和同业存放款项 净增加额向中央银行借款净增加额向其他金融机构拆入资金 净增加额收到原保险合同保费取得 的现金收到再保险业务现金净额保户储金及投资款净增加 额处置交易 性金融资产净增 加额收取利息、手续费及佣金的现金拆入资金净增加额回购业务资金净增加额收到的税费返还收到其他与经营活动有关 的现金4,395,161.452,715,384.5919,197,929.2713,740,645.26经营活动现金流入小计142,268,887.63128,637,073.77120,125,7

16、48.40107,179,574.39购买商品、接受劳务支付的 现金62,581,000.0974,321,439.1120,404,827.2436,172,012.52客户贷款及垫款净增加额存放中央银行和同业款项 净增加额支付原保险合同赔付款项 的现金支付利息、手续费及佣金的 现金支付保单红利的现金支付给职工以及为职工支 付的现金7,553,769.126,097,164.716,078,716.055,190,062.24支付的各项税费20,035,225.9116,244,107.6127,513,258.3920,257,412.32支付其他与经营活动有关 的现金17,861,429

17、.7217,265,679.529,731,101.648,805,103.81经营活动现金流出小计108,031,424.84113,928,390.9563,727,903.3270,424,590.89经营活动产生 的现金 流量净额34,237,462.7914,708,682.8256,397,845.0836,754,983.50二、投资活动产生的现金流量：收回投资收到的现金744,734.62744,734.62取得投资收益收到的现金663,950.00663,750.00处置固定资产、无形资产和 其他长期资产收回的现金净额29,000.0029,000.00处置子公司及其 他营业

18、单 位收到的现金净额收到其他与投资活动有关 的现金投资活动现金流入小计663,950.001,437,484.62773,734.62购建固定资产、无形资产和 其他长期资产支付的现金18,176,403.9615,099,813.248,367,350.704,895,630.75投资支付的现金500,000.0037,222,752.5036,242,220.00质押贷款净增加额取得子公司及其他营业单 位支付的现金净额支付其他与投资活动有关 的现金投资活动现金流出小计18,176,403.9615,599,813.2445,590,103.2041,137,850.75投资活动产生的现金 流量净额-17,